🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “Taiho” Clear

  1. Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine

    Taiho Pharma Netherlands B.V.

    Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 3 small molecule active

    1 trial

  2. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  3. Futibatinib, FULVESTRANT

    Taiho Pharma Netherlands B.V.

    Malignant Solid Tumors

    phase 3 small molecule active

    1 trial

  4. Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Taiho Pharma Netherlands B.V.

    Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations

    phase 3 small molecule active

    1 trial

  5. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  6. ASTX727, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  7. CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  9. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  10. A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors

    Taiho Pharma Netherlands B.V.

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  11. ASTX727, ASTX727, Decitabine, ASTX727

    Taiho Pharma Netherlands B.V.

    Myelodysplastic Syndromes (MDS)

    phase 1 small molecule active

    1 trial

  12. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  13. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources